Open-label multicenter study to determine the effect of ocrelizumab on leptomeningeal inflammation in multiple sclerosis (legato)
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The primary efficacy objective for this study is to determine the evolution of leptomeningeal lesions in patients with active progressive multiple sclerosis (MS) based on the following endpoint:
MRI lesions
Other measures (1)
•The change from the Baseline visit in LMCE foci at the Month 12 visit in the LMCE- positive group.
Who could take part
Progressive MS
Inclusion: •Signed Informed Consent Form. Exclusion: •Inability to provide informed consent.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary efficacy objective for this study is to determine the evolution of leptomeningeal lesions in patients with active progressive multiple sclerosis:
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen R…
Phase 1 / Phase 2 · Not yet recruiting
Still running
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Prog…
Phase 1 · Paused
Still running
- Mintaka
Phase 2 · Recruiting
Still running
- The Effect of Rituximab on Cognitive and Hand Functions i…
Phase 2 · Recruiting
Still running
- ORATORIO-Cort
Completed
No result found
- ORATORIO-CP
Completed
No result found
History
Started
Dec 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error